Home > Journals > Minerva Forensic Medicine > Past Issues > Minerva Forensic Medicine 2021 December;141(4) > Minerva Forensic Medicine 2021 December;141(4):62-7



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as


ORIGINAL ARTICLE   Free accessfree

Minerva Forensic Medicine 2021 December;141(4):62-7

DOI: 10.23736/S2784-8922.22.01813-1


language: English

FAM3D levels in women with gestational diabetes

Murat AKSIT 1, Merve ZEYTINLI AKSIT 2 , Yasemin ALAN 3

1 Department of Medical Biochemistry, Tepecik Training and Research Hospital, University of Health Sciences, Izmir, Turkey; 2 Department of Medical Biochemistry, Bakircay University Cigli Education and Research Hospital, Izmir, Turkey; 3 Clinic of Obstetrics and Gynecology, Izmir Metropolitan Municipality Esrefpasa Hospital, Izmir, Turkey

BACKGROUND: Gestational diabetes mellitus (GDM) is recognized as one of the most common medical complications in pregnant women. The aim of this study was to compare the FAM3D levels of patients with GDM and the control group consisting of pregnant and healthy women without diabetes and to investigate the relationship between the FAM3D molecule and metabolic parameters.
METHODS: Fifty-seven GDM patients, 59 non-GDM pregnant women, and 63 age-matched healthy women were included in this study. The diagnosis of GDM was made by OGTT performed between the 24th and 28th weeks of pregnancy, in accordance with the criteria of the American Diabetes Association (ADA).
RESULTS: FAM3D levels of the GDM group were found to be statistically significantly lower than both the pregnant and healthy control groups (P<0.001). There was a significant negative correlation between FAM3D and BMI, waist circumference, glucose 1 h-OGTT, glucose 2 h-OGTT, insulin, HOMA-IR, total cholesterol, HDL, LDL, triglyceride, and CRP levels. A significant positive correlation was found between urea and urea.
CONCLUSIONS: The lower FAM3D levels in the GDM group suggest that FAM3D may be an early indicator of the pathophysiological process or a therapeutic target for antidiabetic drugs.

KEY WORDS: Diabetes, gestational; Glucagon; Pregnancy; Insulin

top of page